Angiogenesis and antiangiogenic treatment in plazmocytoma

Abstract

Angiogenesis plays a key role in carcinogenesis and it is a stabile pathomorphologic symptom of plasmocytoma. Consequently antiangogenic agents are succesfully introduced to plasmocytoma therapy as well as monoclonal antibodies.
Recently a great interest has been observed in antiangiogenic therapy. In clinical studies of various phase there are many molecules targeted on angiogenesis inhibition. Numerous facts indicate that antiangiogenic therapy will improve cancer treatment outcomes in future.